Opinion

Video

Emerging Evidence on the Treatment of Obesity

In this episode of MEDcast, Diana Isaacs and Natalie Bellini interview Dr. Ken Fujioka, an endocrine specialist, to discuss practice guidelines on obesity treatment and the evolution of anti-obesity medications over the last decade.

1:20 Obesity-associated metabolic disturbances

5:37 When to start medication for obesity

8:28 Metabolic pathways leading to weight gain

13:19 Long-term impact of weight fluctuations

16:07 GLP-1 agonists for weight loss

20:26 Insurance coverage for anti-obesity medications (AOMs)

24:50 Combining lifestyle changes with AOMs

26:27 ‘Super-responders’ to GLP-1 agonist therapies

30:51 Non-responders to GLP-1 agonist therapies

37:28 Comprehensive approach to weight management

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.